Fifty-eight percent of infants treated with roflumilast cream 0.05% achieved EASI-75 at Week 4 in an open-label Phase 2 study (n=101), with low, mostly mild-to-moderate adverse events, one discontinuation, and no serious adverse events. The most frequent events (≥3%) were diarrhea, nasopharyngitis, upper respiratory tract infection, and vomiting.
Arcutis reported topline results from INTEGUMENT-INFANT, a four-week, once-daily trial in patients aged 3 months to less than 24 months with mild to moderate atopic dermatitis. The readout supports the company’s plan to submit an sNDA in Q2 2026 to extend Zoryve’s pediatric label downward to infants. Today, roflumilast cream 0.05% is indicated in the U.S. for ages 2 to 5 years, while the 0.15% strength is indicated for patients 6 years and older. The infant program builds on prior maximal-use pharmacokinetics data in this age group and pivotal data in 2- to 5-year-olds.
Strategically, Arcutis is moving to complete an age-continuum label across topical PDE4 therapy in atopic dermatitis, a space where nonsteroidal options compete on tolerability, usability in sensitive areas, and caregiver preference rather than head-to-head efficacy differentials. By targeting infants—where face and diaper-area use increases concerns about systemic exposure and steroid use—roflumilast’s once-daily regimen and safety consistency across adjacent pediatric cohorts become the core of the regulatory and commercial case. The open-label design signals a bridging strategy: extrapolate efficacy from older populations and anchor infant labeling on PK and safety under maximal-use conditions, a pathway FDA often entertains in pediatric dermatology when disease biology and exposure-response are consistent.
For sites and CROs, the study reflects growing demand for short-duration, caregiver-centric pediatric dermatology protocols with high scrutiny on occluded-area exposure and practical endpoints like EASI-75 and IGA. If the label expands, pediatric dermatology networks may see increased prescription volumes for steroid-sparing treatment on sensitive skin, with operational implications for caregiver education and adherence monitoring. Payers will test the value proposition against low-cost topical steroids and existing nonsteroidal options already labeled to 3 months of age, with formulary decisions hinging on usability claims (once-daily dosing, broad body-area applicability) and real-world discontinuation rates. For sponsors, the approach underscores an increasingly common pediatric playbook: establish efficacy in an older group, then bridge downward with PK, safety, and targeted duration studies that limit sample size and site burden while meeting regulatory sufficiency.
What matters next is whether FDA accepts the totality of evidence without requiring a randomized, controlled infant study. The current dataset offers a robust signal but lacks a comparator; durability beyond four weeks, caregiver-reported itch outcomes, and maximal-use PK detail—especially in face and diaper regions—will be closely scrutinized. Any label nuance restricting use on occluded or sensitive areas would blunt the commercial thesis. On the market side, payers and prescribers will look for clear differentiation versus other nonsteroidal topicals in infants, including adherence advantages from once-daily dosing. Watch for full data disclosure, specifics of the sNDA package, and any parallel EMA engagement. A faster path would validate the extrapolation strategy and accelerate uptake; a request for additional controlled data would extend timelines and increase study complexity in an age group that is operationally hard to enroll and manage.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
